Persistent L-Dopa Responsive Hemiparkinsonism After Cryptococcoal Meningoencephalitis in an Immunocompetent Man
Objective: Our objective is to report a case of persistent L-dopa responsive hemiparkinsonism after Cryptococcal meningoencephalitis in an immunocompetent man. Background: Fungal infections of the CNS are…Motor rigidity selectively associates with impaired odor identification in Parkinson’s disease
Objective: To investigate the relationship between impairments of the cardinal motor symptoms and odor identification deficits in Parkinson's disease (PD). Background: Although hyposmia has been…Comparative study of the substantia nigra echogenicity and 123-I ioflupane SPECT in patients with REM behavior disorder
Objective: To compare (1) the echogenicity of substantia nigra (SN) in subjects with idiopathic REM behavior disorder (iRBD) and healthy controls and (2) to determine…Dat-SPECT in multiple system atrophy (MSA)
Objective: To evaluate the extent of degeneration in dopamine nerve terminal in striatum with the patients with MSA, and compared between subtypes and disease duration…Localization and functional study of synaptic vesicle protein synaptogyrin-3 (SYNGR3) on dopaminergic neuronal system
Objective: To investigate (1) the intracellular localization of SYNGR3 and its interaction with dopamine transporter (DAT); (2) how expression of SYNGR3 in neurons affects dopamine…Dissecting the molecular mechanisms of Fyn-mediated levodopa induced dyskinesias
Objective: To investigate the crosstalk between D1 receptor (D1R) and the signaling of Fyn protein kinase in a mice model of levodopa (L-DOPA) induced dyskinesias…Neurodegeneration and microgliosis are independent of α-synuclein aggregation in a mouse model of "prion-like" α-synuclein speading
Objective: Our aim was to test if α-synclein aggregation drives neuronal demise and microglial activation in a murine model of induced-α-synucleinopathy. Background: Pathological α-synuclein aggregates…Striatal PDE10 expression in Parkinson’s disease (PD) and healthy controls using [18F]MNI-659 PET imaging
Objective: To evaluate the feasibility of [18F]MNI-659 PET, a striatal PDE10A imaging tracer, as a imaging biomarker in PD. Background: PDE10 is highly and specifically…The association between structural brain connectivity with plasma APO-A1 levels in Parkinson’s disease: Connectometry approach
Objective: Features of the lipid profile specially cholesterol levels are association with PD risk. However no such data exists on the association of these plasma…Nigrostriatal degeneration and serum BDNF levels in patients with “de novo” untreated Parkinson’s disease
Objective: To evaluate serum Brain-Derived NeurotrophicFactor(BDNF) levels in “de novo” untreated Parkinson's disease (PD) patients and their relationship to nigrostriatal degeneration measured with [123I]FP-CIT SPECT.…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.